NCT06123975 Adenomyosis Patients With Infertility and Immunological Factors
| NCT ID | NCT06123975 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Third Hospital |
| Condition | Adenomyosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2025-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-03-01 with a primary completion date of 2025-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Infertile patients with adenomyosis who met the inclusion and exclusion criteria, after signing the informed consent form, the researchers recorded the clinical information of the patients and initiated the in vitro fertilization-embryo transfer (IVF-ET) procedure. Peripheral blood was collected on the day of embryo transfer. And if the pregnancy test was positive at 14 days after embryo transfer, peripheral blood was collected at 21 days after the transfer and every 2 weeks thereafter until 12 weeks of gestation. By analyzing the changes of immune cells and molecules in the peripheral blood of the patients, role of immune factors in infertility combined with adenomyosis was further explored.
Eligibility Criteria
Inclusion Criteria: * Patients were diagnosed as adenomyosis by transvaginal ultrasound scans (The criteria for sonographic diagnosis of adenomyosis are with 2 or more of the following: heterogeneous myometrial texture with the presence of globular asymmetric uterus, thickening of the anterior and posterior myometrial wall, irregular cystic areas within the myometrium); * 18≤ age ≤ 40 years old at first outpatient visit in our Reproductive Center; * with regular menstrual cycle. Exclusion Criteria: * Patients with intrauterine adhesion, uterine malformation, submucosal leiomyoma, or ≥ 5.0 cm in diameter leiomyoma; * hydrosalpinx and systemic diseases; * patients with other endocrine severe diseases, immune diseases, tumors and abnormal chromosomes in either partner.
Contact & Investigator
Wen Zhang
PRINCIPAL INVESTIGATOR
Peking University Third Hospital
Frequently Asked Questions
Who can join the NCT06123975 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Adenomyosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06123975 currently recruiting?
Yes, NCT06123975 is actively recruiting participants. Contact the research team at chaodongxiehe@163.com for enrollment information.
Where is the NCT06123975 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06123975 clinical trial?
NCT06123975 is sponsored by Peking University Third Hospital. The principal investigator is Wen Zhang at Peking University Third Hospital. The trial plans to enroll 200 participants.